The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin

Myron S. Czuczman, Julie Marie Vose, Thomas E. Witzig, Pier L. Zinzani, Rena Buckstein, Jonathan Polikoff, Ju Li, Dennis Pietronigro, Annetti Ervin-Haynes, Craig B. Reeder

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12·8months after a median follow-up of 5·6months. Median progression-free survival was 5·4months. Among patients with tFL, ORR was 57%, with a median response duration of 12·8months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.

Original languageEnglish (US)
Pages (from-to)477-481
Number of pages5
JournalBritish Journal of Haematology
Volume154
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Non-Hodgkin's Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Follicular Lymphoma
Disease-Free Survival
Histology
lenalidomide

Keywords

  • Lenalidomide
  • Transformed chronic lymphocytic leukaemia
  • Transformed follicular lymphoma
  • Transformed lymphoma
  • Transformed small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. / Czuczman, Myron S.; Vose, Julie Marie; Witzig, Thomas E.; Zinzani, Pier L.; Buckstein, Rena; Polikoff, Jonathan; Li, Ju; Pietronigro, Dennis; Ervin-Haynes, Annetti; Reeder, Craig B.

In: British Journal of Haematology, Vol. 154, No. 4, 01.08.2011, p. 477-481.

Research output: Contribution to journalArticle

Czuczman, Myron S. ; Vose, Julie Marie ; Witzig, Thomas E. ; Zinzani, Pier L. ; Buckstein, Rena ; Polikoff, Jonathan ; Li, Ju ; Pietronigro, Dennis ; Ervin-Haynes, Annetti ; Reeder, Craig B. / The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. In: British Journal of Haematology. 2011 ; Vol. 154, No. 4. pp. 477-481.
@article{26eaa9cf0cb54d398b134976a85618fd,
title = "The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin",
abstract = "Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25mg/d. The overall response rate (ORR) was 46{\%}, with a median response duration of 12·8months after a median follow-up of 5·6months. Median progression-free survival was 5·4months. Among patients with tFL, ORR was 57{\%}, with a median response duration of 12·8months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.",
keywords = "Lenalidomide, Transformed chronic lymphocytic leukaemia, Transformed follicular lymphoma, Transformed lymphoma, Transformed small lymphocytic lymphoma",
author = "Czuczman, {Myron S.} and Vose, {Julie Marie} and Witzig, {Thomas E.} and Zinzani, {Pier L.} and Rena Buckstein and Jonathan Polikoff and Ju Li and Dennis Pietronigro and Annetti Ervin-Haynes and Reeder, {Craig B.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1111/j.1365-2141.2011.08781.x",
language = "English (US)",
volume = "154",
pages = "477--481",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin

AU - Czuczman, Myron S.

AU - Vose, Julie Marie

AU - Witzig, Thomas E.

AU - Zinzani, Pier L.

AU - Buckstein, Rena

AU - Polikoff, Jonathan

AU - Li, Ju

AU - Pietronigro, Dennis

AU - Ervin-Haynes, Annetti

AU - Reeder, Craig B.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12·8months after a median follow-up of 5·6months. Median progression-free survival was 5·4months. Among patients with tFL, ORR was 57%, with a median response duration of 12·8months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.

AB - Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12·8months after a median follow-up of 5·6months. Median progression-free survival was 5·4months. Among patients with tFL, ORR was 57%, with a median response duration of 12·8months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.

KW - Lenalidomide

KW - Transformed chronic lymphocytic leukaemia

KW - Transformed follicular lymphoma

KW - Transformed lymphoma

KW - Transformed small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=79960834399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960834399&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08781.x

DO - 10.1111/j.1365-2141.2011.08781.x

M3 - Article

VL - 154

SP - 477

EP - 481

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -